Passa al contenuto
Merck
Tutte le immagini(4)

Documenti

P4394

Sigma-Aldrich

cis-Diammineplatinum(II) dichloride

≥99.99% (trace metal analysis), crystalline, anti-neoplastic agent drug

Sinonimo/i:

cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula condensata:
Pt(NH3)2Cl2
Numero CAS:
Peso molecolare:
300.05
Numero CE:
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

product name

cis-Diammineplatinum(II) dichloride, crystalline

Forma fisica

crystalline

Colore

yellow

Punto di fusione

270 °C (lit.)

Spettro attività antibiotica

neoplastics

Modalità d’azione

DNA synthesis | interferes

Ideatore

Corden

Stringa SMILE

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
LXZZYRPGZAFOLE-UHFFFAOYSA-L

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

cis-Diammineplatinum(II) dichloride has been used:
  • in cell viability measurement in cochlear explants
  • in the inhibition of cell proliferation and chemosensitivity in ovarian cancer cell lines
  • in MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] cell viability assay in oral squamous cell carcinoma

Azioni biochim/fisiol

Potent chemoimmunotherapeutic drug; stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin-treated macrophages show increased antigen presentation function in vitro. Treatment increased cellular NF-κB content and translocation in macrophages. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand crosslinks.
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Caratteristiche e vantaggi

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Caspases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Corden. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Stoccaggio e stabilità

This product is to be stored in room temperature. Keep the product tightly closed in a well-ventilated place. Dry. Please view the Safety Data Sheet for more information.

Pittogrammi

Skull and crossbonesHealth hazard

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Cisplatin impurity A European Pharmacopoeia (EP) Reference Standard

Y0001018

Cisplatin impurity A

Oxaliplatin powder

Sigma-Aldrich

O9512

Oxaliplatin

Paclitaxel from Taxus brevifolia, ≥95% (HPLC), powder

Sigma-Aldrich

T7402

Paclitaxel

Doxorubicina 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicina

Calpain system protein expression and activity in ovarian cancer
Zhang S, et al.
Journal of Cancer Research and Clinical Oncology, 1-17 (2018)
Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance
Alam M, et al.
Head & Neck (2018)
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
Lin Hou et al.
Life sciences, 232, 116561-116561 (2019-06-28)
The poor prognosis of ovarian cancer is mainly caused by chemotherapy resistance. Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. However, the mechanism of ABT737 increases sensitivity to cisplatin
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring

Articoli

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.